Black Diamond Therapeutics, Inc. (BDTX): R&D Expense
$33.56M
Year ended 2025-12-31
$28.13M
Trailing 12 months to 2026-06-30
-19.5%
3-year compound annual growth
-7.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.56M | -34.6% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $51.31M | -13.5% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $59.35M | -7.9% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $64.44M | -33.5% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $96.83M | +100.9% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $48.21M | +121.6% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $21.75M | +213.0% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $6.95M | n/a | 2020-03-24, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $33.56M | -34.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $455.97M | -10.0% |
| Compugen Ltd (CGEN) | 2025-12-31 | $22.76M | -8.3% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $475.27M | +51.2% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $117.69M | -15.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $195.70M | +38.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $38.31M | -72.1% |
Compare BDTX, VIR, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗